Comparison · NCT00103740-23bba751
Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period. Trial comparisons, record NCT00103740-23bba751. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00103740-23bba751
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.128 | 0.0712 | 0.22 | wilson | |
| Risk in group 2 | 0.667 | 0.544 | 0.771 | wilson | |
| Risk difference, group 1 minus group 2 | -0.538 | -0.657 | -0.385 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.192 | 0.105 | 0.352 | log | |
| Odds ratio, group 1 over group 2 | 0.0735 | 0.0316 | 0.171 | log | |
| Number needed to treat, for one fewer participant with the outcome on Zoledronic Acid and Placebo to Risedronate than on Risedronate and Placebo to Zoledronic Acid | 1.86 | 1.52 | 2.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Zoledronic Acid and Placebo to Risedronate | Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period. | 10 | 78 | OG000 |
| Group 2 | Risedronate and Placebo to Zoledronic Acid | Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period. | 42 | 63 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period
- Description
- Extended observation period. A therapeutic response is defined as a reduction of at least 75% from baseline in serum alkaline phosphatase excess or normalization of serum alkaline phosphatase.
- Time frame
- 8 years was the maximum
- Population
- Extended modified Intent-to-treat population: patients who had at least one serum alkaline phosphatase measurement during the extension period.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
- NCT number
- NCT00103740
- Phases
- PHASE3
- Conditions
- Paget's Disease of Bone
- Interventions
- zoledronic acid, placebo to zoledronic acid, Risedronate, Placebo to risedronate, Calcium and vitamin D supplements
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2012-05-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00103740?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00103740-23bba751